New Branched Polymer Excipients and Emulsions for Enhanced Drug Delivery
- Funded by UK Research and Innovation (UKRI)
- Total publications:0 publications
Grant number: EP/R024804/1
Grant search
Key facts
Disease
COVID-19start year
2018Known Financial Commitments (USD)
$2,296,501.09Funder
UK Research and Innovation (UKRI)Principal Investigator
Andrew OwenResearch Location
United KingdomLead Research Institution
University of LiverpoolResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
This translational science research aims to build upon ongoing work across University of Liverpool and Liverpool School of Tropical medicine. The work aims to accelerate preclinical validation of drugs for Covid-19 treatment and/or prevention. To maximise healthcare impact, the work seeks to establish three direct outputs, namely; 1) Selection of candidates based on in vitro anti-SARS-CoV-2 activity, 2) Demonstration of In vivo pharmacokinetics and distribution supporting treatment and prevention applications, and 3) Demonstration of in vivo performance in mice infected with SARS-CoV-2. We expect the research to provide evidence-based candidates for evaluation in human clinical trials. We will also undertake additional evaluations for low-middle income settings, focussing on scalability and affordability in sub-Saharan Africa and preferring orally delivered medications, with little or no laboratory monitoring.